FDA Approved: WYOST — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for WYOST (denosumab) submitted by Sandoz Inc, expanding the product's indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases From Solid Tumors
• Breast Cancer with Bone Metastases
• Hypercalcemia of Malignancy
• Osteoporosis
• Postmenopausal Osteoporosis
• Prostate Cancer with Bone Metastases

Drugs mentioned

• WYOST (Denosumab)

Snippet

SUPPL AP for WYOST (DENOSUMAB)